A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with ...

Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...

Novo Nordisk in West Lebanon is looking to hire 40 people in 2024, a 10% increase in its current headcount of about 400 as it continues its work to improve the lives of people with certain ailments. A ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on ...

LONDON, Sept 11 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index by 7.4% in a 56 ...

DSV A/S’s new acquisition, the $15.9 billion takeover of DB Schenker, will almost double the freight company’s sales, making it Denmark’s second-largest firm by that measure and pushing Novo ...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers. It needs next generation innovation and growth in emerging markets to keep ahead of competitors ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Shares in Novo, which presented full data from the Phase I study at the European Association for the Study of Diabetes meeting in Madrid, were trading up 2.4% at 1307 GMT. "What we see in the ...

Novo Nordisk's GLP-1 drugs like Ozempic and Wegovy are smash hits. However, another biotech is working on a few programs that could be far better. It has plenty of money, good preliminary results ...

Novo Nordisk A/S is likely to account for about half of Denmark’s economic expansion this year, helping the nation to outperform its Nordic neighbors, according to the country’s largest bank ...

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to ...